Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the recipient of some unusual options trading on Wednesday. Stock traders acquired 21,515 call options on the stock. This is an increase of approximately 1,415% compared to the typical daily volume of 1,420 call options.
Analyst Ratings Changes
Several brokerages have issued reports on XENE. Royal Bank Of Canada raised their price objective on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “outperform” rating in a research note on Friday, May 8th. Needham & Company LLC cut their target price on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Monday. HC Wainwright upped their price objective on Xenon Pharmaceuticals from $53.00 to $74.00 and gave the company a “buy” rating in a research report on Tuesday, March 10th. Finally, JPMorgan Chase & Co. increased their target price on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 27th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $77.20.
Read Our Latest Report on XENE
Xenon Pharmaceuticals Trading Up 10.4%
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) EPS for the quarter, hitting the consensus estimate of ($1.17). During the same period in the previous year, the company earned ($0.83) EPS. As a group, research analysts anticipate that Xenon Pharmaceuticals will post -4.92 EPS for the current fiscal year.
Insider Buying and Selling at Xenon Pharmaceuticals
In other Xenon Pharmaceuticals news, Director Gillian Cannon sold 1,190 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $63,236.60. Following the transaction, the director owned 1,455 shares in the company, valued at $77,318.70. The trade was a 44.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Gary Patou sold 1,322 shares of the stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $70,251.08. Following the completion of the sale, the director directly owned 24,896 shares in the company, valued at approximately $1,322,973.44. This represents a 5.04% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 4.07% of the company’s stock.
Hedge Funds Weigh In On Xenon Pharmaceuticals
Institutional investors have recently made changes to their positions in the company. Cinctive Capital Management LP raised its holdings in shares of Xenon Pharmaceuticals by 1.1% in the fourth quarter. Cinctive Capital Management LP now owns 23,317 shares of the biopharmaceutical company’s stock valued at $1,045,000 after acquiring an additional 263 shares in the last quarter. State of Wyoming grew its holdings in Xenon Pharmaceuticals by 30.4% during the 4th quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company’s stock worth $67,000 after acquiring an additional 350 shares in the last quarter. Quarry LP grew its holdings in Xenon Pharmaceuticals by 25.0% during the 3rd quarter. Quarry LP now owns 2,500 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 500 shares in the last quarter. Altfest L J & Co. Inc. increased its position in Xenon Pharmaceuticals by 6.5% during the 4th quarter. Altfest L J & Co. Inc. now owns 8,232 shares of the biopharmaceutical company’s stock valued at $369,000 after purchasing an additional 501 shares during the period. Finally, Royal Bank of Canada raised its holdings in shares of Xenon Pharmaceuticals by 0.7% in the 1st quarter. Royal Bank of Canada now owns 90,387 shares of the biopharmaceutical company’s stock valued at $5,255,000 after purchasing an additional 630 shares in the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.
The company’s pipeline comprises multiple preclinical and clinical programs.
Featured Articles
- Five stocks we like better than Xenon Pharmaceuticals
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
- Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
